{
  "id": 4423379,
  "title": "Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial",
  "url": "https://urgent.news/2026/08/30/eplontersen-with-and-without-background-transthyretin-stabilizers-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-30T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04670-6"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 30 August 2026; doi:10.1038/s41591-026-04670-6 As presented at the 2026 ESC Congress, in a secondary analysis of the CARDIOTTRansform trial testing the transthyretin-targeting antisense oligonucleotide eplontersen in patients with transthyretin amyloid cardiomyopathy, a beneficial effect was observed in patients who were not on transthyretin stabilizers at…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy",
        "url": "https://urgent.news/2026/08/29/eplontersen-trial-fails-to-meet-primary-endpoint-in-transthyretin",
        "published": "2026-08-29T02:40:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}